Loading... Please wait...

iLite® anti-HER2 ADCC Activity Set

Hover over image to zoom

$1,850.00
SKU:
BM4090

 Product Description

Product Specs view pdf
Product Poster view pdf
 

 

 

iLite® Anti-HER2 ADCC Activity Set :

Set Includes: (components also available separately)

Product Developed and Manufactured by EuroDiagnostica
For Research Use Only

 Application notes for the following assays are available:

 Storage:  -80°C, Cells should be used within 30 min of thawing.

Summary

The products included in the iLite® anti-HER2 ADCC Activity Set can be used for the quantification ADCC activity of anti-HER2 antibodies.

Background:

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell.

Breast cancer is the most common cancer in women worldwide, and the second most common cancer overall. Survival rates have improved in the recent years, and stratification of patients into subgroups has vastly improved treatment options for many patients. As an example, patients with HER2 positive breast cancer generally have a poor prognosis, but treatment with trastuzumab, a monoclonal antibody targeting the HER2 receptor, has shown to increase both overall survival and disease free survival when given together with chemotherapy. Trastuzumab’s mechanism of action is mediated in part by inducing ADCC when crosslinking HER2 positive cells with the patient's immune cells. The drug was FDA approved for treatment of breast cancer patients in 1998, and many biosimilars are currently in development.

 

 

FIGURE 1: The interaction between the reporter gene Effector cell and the Target cell, generated by the crosslinking via a specific drug antibody. The resulting luminescence originates exclusively from this crosslinking and the signaling from the CD16 receptor to the Firefly Luciferase.

 

 

 

FIGURE 2: When the Target cell have been depleted for the specific surface target molecule, the crosslinking between the Effector and the Target cell cannot be established and hence no luminescence from Firefly Luciferase is generated. But luminescence from NanoLuc, which is expressed under a constitutive promotor, is still present.

 

Key benefits of iLite® ADCC Activity Assays:

  • Unparalleled sensitivity
  • High serum tolerance
  • Normalization read-out included
  • Negative control available for screening of unspecific activity
  • Easy to use – no culturing required on target or effector cells

 

 

 Find Similar Products by Category

Vendors Other Products

Eagle Biosciences, Inc.
20A NW Blvd., Suite 112
Nashua, NH 03063
Email: info@eaglebio.com
Toll Free: (866) 411-8023
International: +617-419-2019

Click the button below to add the iLite® anti-HER2 ADCC Activity Set to your wish list.